MRLinac Boost for Gynecological Cancers if Brachytherapy is Not Feasible (MARGARITA)

Sponsor

UMC Utrecht (Other)

Overall Status

Recruiting

CT.gov ID

NCT05937958

Collaborator

Odense University Hospital (Other)

Enrollment

Locations

Anticipated Duration (Months)

Patients Per Site

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this observational study is to explore the effectiveness and side effects of a high dose daily adapted SBRT (stereotactic body radiotherapy) boost delivered with MRLinac in patients with gynaecological cancers that cannot receive a brachytherapy boost to the primary tumour for different reasons (medical conditions, tumour extensions, etc). Current alternative for brachytherapy in these situations is often a non-adaptive conebeam- CT guided boost. Conebeam-CT guided non-adaptive high dose SBRT in under these circumstances is described being quite toxic.

The main questions this study aims to answer are:

In how many cases could local control (i.e. total disappearance of the tumor) is be achieved with this treatment?
Which side effects are observed in patients receiving this treatment?

Participants will be asked to fill out questionnaires (e.g. regarding side effects). Furthermore, participants are asked if their clinical data may be used for study purposes.

Condition or Disease	Intervention/Treatment	Phase
Cervical Cancer Gynecologic Cancer

Detailed Description

Standard treatment of locally advanced cervical cancer is chemoradiotherapy (external beam radiotherapy (EBRT) and concomitant chemotherapy with weekly Cisplatin) followed by image guided brachytherapy (IGBT). Recently, the MR Linac has emerged as new option for delivering an external beam radiotherapy boost to the primary cervical tumour after (chemo)radiaton in case brachytherapy is not feasible. MR Linac in these cases can replace traditional EBRT boosts and allow for better visualisation of the anatomy, smaller treatment margins and online treatment planning adaptation. This comes with potential for higher dose to the target and less dose to the surrounding organs.

Like in IGBT, an MRL treatment provides the possibility to perform repetitive imaging before and even during each fraction and allows for dose adaptation to anatomical changes in individual patients. This way not not only the daily position of OARs in relation to the target can be taken into account, but also possible tumor regression which often is obtained during chemoradiation. Based on the experience collected so far, the MRL treatment may be an interesting treatment option in selected cases as daily MRI and plan adaptation leads to more confined dose distribution compared to CBCT-Linac options. However, dose levels for the MRL-boost are likely to be lower than for IGBT, therefore its effectiveness is still unsure.

Aims of the study:

To introduce MRL-boost in locally advanced cervical cancer in a multicenter setting within the frame of a prospective observational study.
To establish a bench-mark for clinical outcome with MRL-boost in a multi-center patient population with respect to local control, survival and toxicity.
To establish reference material with regard to MRL-based DVH parameters; if applicable delineations according to the guidelines from the GEC-ESTRO gynecology working group will be used.
To report image-based DVH parameters for target (GTV, CTV, PTV) and for OARs
To report recurrence patterns
To report Quality of Life

Type of design

This study is a multicenter prospective observational study. Patient registration and dosimetric reporting will be performed in the individual centers.

Study Design

Study Type:

Observational

Anticipated Enrollment :

30 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

MRLinac Boost for Gynecological Cancers if Brachytherapy is Not Feasible

Actual Study Start Date :

Apr 1, 2023

Anticipated Primary Completion Date :

Oct 1, 2025

Anticipated Study Completion Date :

Oct 1, 2027

Outcome Measures

Primary Outcome Measures

Local control [3 months after MRLinac treatment]
Local control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.
Local control [6 months after MRLinac treatment]
Local control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.
Local control [12 months after MRLinac treatment]
Local control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.
Local control [24 months after MRLinac treatment]
Local control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

Secondary Outcome Measures

Regional control [3 months after MRLinac treatment]
Regional control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.
Regional control [6 months after MRLinac treatment]
Regional control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.
Regional control [12 months after MRLinac treatment]
Regional control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.
Regional control [24 months after MRLinac treatment]
Regional control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.
Distant failure [3 months after MRLinac treatment]
Distant failure of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care
Distant failure [12 months after MRLinac treatment]
Distant failure of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care
Distant failure [24 months after MRLinac treatment]
Distant failure of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care
Gastrointestinal toxicity [3 months after MRLinac treatment]
Gastrointestinal toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)
Gastrointestinal toxicity [6 months after MRLinac treatment]
Gastrointestinal toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)
Gastrointestinal toxicity [24 months after MRLinac treatment]
Gastrointestinal toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)
Urogenital toxicity [3 months after MRLinac treatment]
Urogenital toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)
Urogenital toxicity [6 months after MRLinac treatment]
Urogenital toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)
Urogenital toxicity [24 months after MRLinac treatment]
Urogenital toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)
Vaginal toxicity [3 months after MRLinac treatment]
Vaginal toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)
Vaginal toxicity [6 months after MRLinac treatment]
Vaginal toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)
Vaginal toxicity [24 months after MRLinac treatment]
Vaginal toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with newly biopsy proven advanced stage gynecological cancers (excluding ovarian cancers) and endometrium in whom definitive (chemo)radiotherapy with curative intent is planned are qualified for the study, as well as, patients with recurrent gynecological cancers (excluding ovarian cancers) for which no prior (chemo)radiation was performed for which (chemo)radiotherapy with curative intent is planned.
Patients with para-aortic metastatic nodes (stage IVB) to the level of L2 are also eligible but patients with further dissemination are not.
Staging according to FIGO (2018, https://doi.org/10.1002/ijgo.12611) and TNM (version 9, 2021, https://doi.org/10.3322/caac.21663) staging.
Patients who gave informed consent to take part in the MOMENTUM study (NCT04075305) to use their clinical data for publication and share their data with other (European) sites.